Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: Data from the ESPOIR cohort

Annals of the Rheumatic Diseases

Volumn 76, Issue 11, 2017, Pages 1797-1802

  Roubille, Camille ^a   Rincheval, Nathalie ^a   Dougados, Maxime ^b,c   Flipo, René Marc ^d   Daurès, Jean Pierre ^a   Combe, Bernard ^a  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS DESCARTES UNIVERSITY   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Corticosteroids; Early Rheumatoid Arthritis; Outcomes research; Rheumatoid Arthritis

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FRACTURE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; FRANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; TIME FACTOR;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85031013674     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210135     Document Type: Article

References (40)

1. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;(1): CD006356.
2. Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford) 2014;53:1742-51.
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
4. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Ann Rheum Dis 2016;68:1-26.
5. Ethgen O, de Lemos Esteves F, Bruyere O, et al. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin 2013;29:1147-60.
6. Black RJ, Joseph RM, Brown B, et al. Half of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Res Ther 2015;17:375.
7. Albrecht K, Callhoff J, Schneider M, et al. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int 2015;35:1377-84.
8. McKeown E, Bykerk VP, De Leon F, et al. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 2012;51:1662-9.
9. Cardiel MH, Pons-Estel BA, Sacnun MP, et al. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 2012;18:327-35.
10. Gaujoux-Viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. Ann N Y Acad Sci 2014;1318:32-40.
11. Santiago T, da Silva JA. Safety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trials. Neuroimmunomodulation 2015;22:57-65.
12. Combe B, Rincheval N. Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. Joint Bone Spine 2015;82:13-17.
13. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
14. Combe B, Rincheval N, Benessiano J, et al. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 2013;40:1650-7.
15. Aletaha D, Neogi T, Silman AJ, III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
16. Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013;52:68-75.
17. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
18. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
19. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149-56.
20. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 2016;75:952-7.
21. Alten R, Grahn A, Holt RJ, et al. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open 2015;1:e000134.
22. Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open 2016;2:e000203.
23. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.
24. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
25. Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68:1833-8.
26. Sihvonen S, Korpela M, Mustonen J, et al. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 2006;33:1740-6.
27. del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2014;66:264-72.
28. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF? inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
29. Ajeganova S, Svensson B, Hafström I, BARFOT Study Group. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 2014;4:e004259.
30. de Hair M, IJff N, Jacobs J, et al. Long-term adverse events after daily concomitant treatment with 10 mg prednisone in the 2-year computer assisted management in early rheumatoid arthritis trial-II [abstract]. Arthritis Rheumatol 2015;67(Suppl 10):856-7.
31. Caporali R, Todoerti M, Scirè CA, et al. Oral low-dose glucocorticoids should be included in any recommendation for the use of non-biologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. Neuroimmunomodulation 2015;22:104-11.
32. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480-9.
33. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011;78:23-30.
34. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
35. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
36. Haraoui B, Jovaisas A, Bensen WG, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD Open 2015;1:e000078.
37. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010;77:246-51.
38. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128-33.
39. van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015-21.
40. van Sijl AM, Boers M, Voskuyl AE, et al. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS ONE 2014;9: e87965.